UroGen Pharma Ltd. (NASDAQ:URGN) filed a Form 8-K with the Securities and Exchange Commission on March 02, 2026, disclosing a material event.
UroGen Pharma Ltd.'s stock currently trades at $21.70 with a market capitalization of $1.0B. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for UroGen Pharma Ltd.'s stock.
All SEC filings for UroGen Pharma Ltd. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
